Upregulated activity of the Ras-Raf-mitogen-activated protein (MEK)/ERK pathway is associated with prostate cancer progression and poor prognosis, correlating with increased tumor grade of primary or metastatic prostate cancer and tumor relapse after therapy [11–14]. Here, MAP2K7 is linked to neoplasm.